Antibody-Drug Conjugates

Informa Life Sciences’11th AnnualThe average costs of developing a bioSuperior is estimated to be 60% lessthan bringing a new product to market – find out what Medimmune, GSK andMacrogenics are doing to stay on top of this rapidly expanding areaRecombinant &Bispecific AntibodiesPart of:Wednesday 12 & Thursday 13 June 2013, Hotel Fira Palace, Barcelona, SpainAccelerate Product Development with Europe’s Most Industry-Driven Antibody ConferenceFocusing on Ground-Breaking Advances in Targeting, Engineering, Preclinical and ClinicalHear from 25+ speakers, 25+ case studies, 10+ hours of networking with 150+ attendeesSpecialRates forSMEs andAcademicsDr Luis BorgesScientific Director,Therapeutic Innovation UnitAmgen Inc, USADr Jijie GuSenior Principal ScientistAbbvie, USADr Dimiter S DimitrovSenior InvestigatorNational Institute of Health, USADr Mihriban TunaAssociate Vice President, DiscoveryF-Star Biotechnology Ltd, UKDr Eric SmithAssociate Director,Bispecific EngineeringRegeneron, USADr Ezio BonviniSenior Vice President, ResearchMacroGenics, Inc. USABrand New for 2013:4 New pre-conference symposium on target selection for recombinant and bispecific Antibodies4 Dedicated plenary session on building biosuperiority into current antibody formats4 Expanded session on engineering fusion Proteins and antibody fragments4 Explore the pros and cons of current bispecific antibody formats with 8+ case studiesKey Reasons Not to Miss Europe’s Favourite Antibody Conference!4 Benchmark your bispecific, ADC and mAb target selection strategies against Genentech, Medimmune &Bayer - full day pre-conference symposium4 Fast-track your fusion protein, antibody fragment and antibody mixtures development programmes withupdates from Symphogen, Randox Laboratories and NIH4 Optimise your products’ half-life & effector functions with critical insight from Macrogenics and Roche4 Pick a winning bispecific antibody format with advice from market leaders - Amgen, Macrogenics, F-Star,Genentech, Abbott, Glenmark Pharmaceuticals and many more…4 Accelerate your bispecific clinical development programmes with first-hand advice from Sanofi - Aventis,Regeneron and Affimed Therapeutics plus join our evening seminar on Moving Bispecific Antibodiesinto the ClinicChoice of 3 Industry-Led WorkshopsPlus hear from...4 Dr Tilman Schlothauer, Pharma Research and EarlyDevelopment (pRED), Roche, Germany4 Dr Muhammad Al-Hajj, Senior Director, Oncology R&D,GlaxoSmithKline, USA4 Dr Stanislas Blein, Deputy Director, AntibodyEngineering, Glenmark Pharmaceuticals, Switzerland4 Dr Justin Scheer, Scientist, Research and EarlyDevelopment, Genentech, USA4 Dr Andrew Nyborg, Senior Scientist, BiosuperiorEngineering, Medimmune, USA4 Dr John de Kruif, Chief Scientific Officer, Merus,Netherlands4 Dr Ercole Rao, Group Leader Antibody Engineering,Sanofi-Aventis, Germany4 Dr Ralph Minter, Fellow Technology, Antibody Discoveryand Protein Engineering, Medimmune, UK4 Dr Eugene Zhukovsky, Chief Scientific Officer, AffimedTherapeutics AG, SwitzerlandPre-Conference Symposium W: Tuesday 11th June 2013Target Selection for Bispecifics, RABs and ADCsSymposium leaders: Dr Heiner Apeler, Bayer Healthcare, Germany, Dr Nazzareno Dimasi, MedImmune, USA, Dr Rastislav Tamaskovic, University of Zurich,Switzerland, Dr Ralph Minter, MedImmune, UK, Dr Dimiter S Dimitrov, National Institute of Health, USA and Dr Kedan Lin, Genentech, USAEvening Seminar S: Wednesday 12th June 2013Moving Bispecific Antibodies into the ClinicSession speakers: Dr Luis Borges, Amgen Inc, USA, Dr Ercole Rao,Sanofi-Aventis, Germany, Dr Justin Scheer, Genentech, USA, Dr David Poon, Zymeworks,Canada and chaired by Dr Peter Bach, BioPharmaLogic LLC, UKFree EveningSeminar with4 day passNew for2013Post Conference Workshop X: Friday 14th June 2013Engineering Strategies to Reduce Immunogenicity for Antibodies, Fragments and ConjugatesLeader: David Bramhill, Founder, Bramhill Biological Consulting, LLC, USARegister online: www.informa-ls.com/antibodiesCongress Sponsors:Conference Exhibitor:New for2013

Please visit thewebsite for full abstractsand more details!This symposium day will provide an in depth overview of current targetselection technologies for bispecifics, monoclonal antibodies andantibody drug conjugates.Chaired by: Dr Dimiter S Dimitrov, National Institute of Health,USATargeting of HER2 receptor with bispecificDARPin agentsDr Rastislav Tamaskovic, Department of Biochemistry, Universityof Zurich, SwitzerlandPRE-CONFERENCE SYMPOSIUM DAY: TUESDAY 11TH JUNE 2013TARGET SELECTION FOR BISPECIFICS, RABS AND ADCSRegistration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be providedDiscussion Panel: How to optimise the dual targetinggeometry of bispecific antibodiesModerated by the ChairPhenotypic screening for therapeutic antibodies and noveldrug targetsDr Ralph Minter, Fellow, Technology, Antibody Discovery and ProteinEngineering, MedImmune, UKGenentech’s target selection and developability strategiesDr Kedan Lin, Scientist, Early Development PKPD, Genentech, USADevelopability assessment of antibodies and ADCsDr Heiner Apeler, Director, Purification & Research Analytics, BayerHealthcare, GermanyCurrent antibody-drug conjugate technology activities andtechnical challengesDr Nazzareno Dimasi, Senior Scientist, Antibody Discovery & ProteinEngineering, MedImmune, USAPlease check out the websitewww.informa-ls.com/antibodies for more detailsNew for2013Opening Plenary SessionDAY 1: WEDNESDAY 12TH JUNE 201308.00 Registration & Morning Coffee08.55 Opening Remarks from the ChairBuilding BioSuperiority into Current Antibody Formats09.00 UTILISING A BISPECIFIC FORMAT FOR DEVELOPING ADCSOncology application of Dual-Affinity Re-Targeting (DART) moleculesMacroGenics has developed the antibody-based DA RT platform as a versatile way to configurebispecific molecules of varying size and valency. DART proteins are currently being investigatedand developed for oncology applications, including redirected cytolysis via effector cell recruitmentto tumors and the use of DART-drug conjugates. Approaches to identifying optimal DARTspecificities, size and valency will be discussed, including applications of a universal DART(U-DART) screening strategy and site specific conjugation.Dr Ezio Bonvini, MD Senior Vice President, Research, MacroGenics, Inc. USA09.30 KEYNOTE ON IMPROVED TARGETINGNovel approaches for identifying and validating new targets for empoweredantibodiesPlease check the webisite www.informa-ls.com/antibodies for more detailsDr Muhammad Al-Hajj, Senior Director, Oncology R&D, GlaxoSmithKline, USA10.00 Morning Break plus Networking with Empowered Antibodies Delegates10.30 Featured presentationMethods to differentiate and develop BioSuperior antibodiesPlease check the webisite www.informa-ls.com/antibodies for more detailsDr Andrew Nyborg, Senior Scientist, Biosuperior Engineering, MedImmune, USAEffector Function Engineering and Half-Life Optimisation11.00 Antibodies without Fc-gamma Receptor mediated Effector functionsThe constant part (Fc) of the human IgG interacts with various receptors of immune effector cells.The goal of our attempts was to establish the most silent antibody format without exerting anyreceptor mediated effector functions e.g. for therapeutic use in inflammatory diseases. Severalcombinations of mutations have been tested in a comprehensive set of cell free and cell based invitro functional tests, part of our Fc receptor platformDr Tilman Schlothauer, Pharma Research and Early Development (pRED), Roche, Germany11.30 Optimising the half-life of bispecificsPlease check the webisite www.informa-ls.com/antibodies for more detailsDr Syd Johnson, VP, Antibody Engineering, MacroGenics, Inc. USA12.00 Highly specific antibodies binding to therapeutic drugs – new tools for assaydevelopmentThe rapidly increasing number of therapeutic antibodies on the market requires correspondingtools for monitoring the concentration of these drugs in patient samples and for measurementof anti-drug antibodies (ADA). We will present the use of the HuCAL® technology for fastdevelopment of fully human Fab and Ig anti-idiotypic antibodies binding specifically and with highaffinity to well-known drugs like Herceptin®, Avastin®, Rituximab and others. The developmentof antibodies that detect the antibody drug when bound to its target will be shown as well.Dr Achim Knappik, Senior Director, Head of R&D, AbD Serotec (A Bio-Rad Company),Germany12.30 Lunch and Poster Presentation Time plus Networking with Empowered Antibodies DelegatesCutting Edge Advances in Fusion Proteins,Antibody Fragments and Antibody Mixtures14.00 Antibody-cytokine fusions (immunocytokines): from the bench to the clinicPlease check the webisite www.informa-ls.com/antibodies for more detailsProfessor Dario Neri, Department of Chemistry and Applied Bioscience, ETH Zurich,Switzerland14.30 Site specific conjugation of antibody fragmentsA key technology in the production of diagnostic and therapeutic antibody fragments is thedirected conjugation of antibody fragments to detector or effector proteins at a pre-determinedsite and valency which causes no interference to the antibody binding. Considerations andmethods for achieving this aim shall be discussed along with the application of this technologyin the labelling of antibody fragments for the diagnostic measurement of cardiac troponin levelsMarshall Dunlop, Project Leader, Recombinant Antibody Fragments, Randox LaboratoriesLtd, UK15.00 Development of multitarget recombinant antibody mixturesRecombinant antibody mixtures are presently being evaluated as drug candidates to treatserious indications especially within the oncology field. Symphogen has developed differenttechnologies allowing the identification, selection, and manufacturing of multitargetrecombinant antibody mixtures. This presentation will address the analytical challenges ofantibody mixtures relative to monoclonal products and will shown different examples offunctional evaluation of such mixturesDr Torben P. Frandsen, Vice President of PreClinical R&D Support, Symphogen A/S,Denmark15.30 Afternoon Tea plus Networking with Empowered Antibodies DelegatesEngineering Aggregation Resistance in Antibodies16.00 Engineering aggregation Resistance in IgGs based on lessons learned bycomparative expressionOur comprehensive studies have systematically investigated the impact of certain sequences onthe aggregation properties of IgGs using a wide range of biophysical methods and showed thattheir aggregation susceptibilities can be readily engineered. These data offer an improved insightinto the molecular processes causing aggregation and an understanding of the influence ofcertain intramolecular interactions on this process. I will further show evidence that the additionof four amino acids to a protein of several hundred residues can have dramatic effects on itsbiophysical characteristics.Dr Jonas Schaefer, Department of Biochemistry, University of Zurich, SwitzerlandSelecting the Best Bispecific and Multispecific Antibody Format16.30 Keynote PresentationBiTEs: unique single chain bispecific antibodies that redirect polyclonal T cells toeliminate tumorsBiTEs are potent bispecific single-chain antibodies that redirect T cells to kill tumors. They engagea tumor target and a constant region of the T cell receptor to recruit and activate polyclonal Tcells to eliminate tumors. BiTEs bypass the need for T cells to recognise tumor peptides in thecontext of MHC molecules and have a broad therapeutic potentialDr Luis Borges, Scientific Director,Therapeutic Innovation Unit, Amgen Inc, USA17.00 Advancing novel bispecific antibody biologicsF-star’s Modular Antibody Technology will be described where straight forward “mix-and-match”of antibody components can be applied to create unique mAb bispecific antibodies and exploretheir novel biology. An Fcab against a single target, where additional binding sites have beenintroduced to the constant region, can be combined with the variable regions of as manydifferent existing antibodies as desiredDr Mihriban Tuna, Associate Vice President, Discovery, F-star Biotechnology Ltd, UK13.30 Engineered antibody domains/fragments and fusion proteins as candidatetherapeuticsWe constructed large libraries of engineered antibody VH and CH2 domains (eAds) and scFv andmonomeric Fc (mFc) fragments. Binders against cancer-related proteins and viruses from theselibraries were selected and used for construction of mono- and bispecific fusion proteins. Some ofthem have potential as candidate therapeutics against cancer and HIV-1Dr Dimiter S Dimitrov, Senior Investigator, National Institute of Health, USAWhy attend?This workshop will discuss critical attributes of bispecifics (theirstrategic positioning, manufacturing, bioanalytical support, nonclinicaldevelopment, and options for first-time-in-human studies) requiredfor successful clinical development. In a guided interactive roundtablediscussion this workshop will allow you to hear from some ofthe leading bispecific companies in how they envisage they willsuccessfully move their bispecifics into early phase studies, andthrough the clinic to licensing.EVENING SEMINAR S: WEDNESDAY 12TH JUNE 2013MOVING BISPECIFIC ANTIBODIES INTO THE CLINICRegistration 18.30 – Start 18.45 – End 20.30 – Dinner and refreshments will be providedSpecifically this workshop will cover:• Choosing target pairs and the appropriate bispecific antibodyformats• Expression in manufacturing cell lines and purification tohomogeneity• Fc functionality• Stability (manufacturability• PK/PD profile• Non-clinical development• First in human studies17.30 Abbott’s approach for selecting the best bispecific formatsPlease visit the webisite www.informa-ls.com/antibodies for more detailsDr Jijie Gu, Senior Principal Scientist, Abbvie, USA18.00 Closing remarks from the Chairman18.05 End of conference Day 1 and registration opens for the evening seminar on“Moving Bispecific Antibodies into the Clinic”Session leaders:Dr Luis Borges, Scientific Director,Therapeutic Innovation Unit, Amgen Inc, USADr Ercole Rao, Group Leader Antibody Engineering,Sanofi-Aventis, GermanyDr Justin Scheer, Scientist, Research and Early Development,Genentech, USADr David Poon, Director, External R&D and Alliance, Zymeworks,Canada and chaired by Dr Peter Bach, Director, BioPharmaLogicLLC, UKRegister online: www.informa-ls.com/antibodies • Phone: +44 (0) 20 7017 7481Email: registrations@informa-ls.com • Fax: +44 (0) 20 7017 7823 Please Quote: CQ3495

08.25 Opening Remarks from the ChairDAY 2: THURSDAY 13TH JUNE 2013Selecting the Best Bispecific and Multispecific Antibody Format08.30 Bispecific engagement by antibodies based on the T Cell Receptor: BEAT PlatformWe will present a unique solution to the heavy chain heterodimerization problem using a technologyinspired by nature rather than derived from display or mutational screening methods. Using our BEATplatform, we have efficiently engineered and produced at high yield bispecific antibodies or BEATs thattarget growth factor receptors broadly involved in oncology. Technology background and proof-of-conceptstudies will be discussed.Dr Stanislas Blein, Deputy Director, Head Antibody Engineering, Glenmark Pharmaceuticals S.A.,Switzerland.09.00 Antibody fragment phamacokinetics in the eye and implications for bispecific therapeuticsPlease check the webisite www.informa-ls.com/antibodies for more detailsDr Justin Scheer, Scientist, Research and Early Development, Genentech, USA09.30 Interactive discussion panelPros and cons of current bispecific antibody formats• What format for which purpose?• What format for which therapeutic application?• How can we use the best T cell activating technologyJoined by the bisepcific platform session speakers plus moderated by David Bramhill, Founder, BramhillBiological Consulting, LLC, USA10.00 Morning Break plus Networking with Empowered Antibodies DelegatesPreclinical and Clinical Advances for Bispecific Antibodies10.30 Featured PresentationPreclinical developments with a fully human bispecific antibody platformThis presentation will describe the generation of a platform technology that can be used to generate fullyhuman bispecific antibodies through the combination of Fc modifications that allow selective protein Apurification and VelocImmune generated antibodies that utilize a single defined light chain. Molecularcharacterisation and in vitro/in vivo data showing the efficacy of this format will be discussedDr Eric Smith, Associate Director, Bispecific Antibodies, Regeneron, USA11.00 Featured PresentationSAR156597: An innovative bi-specific IL-4/IL-13 antibody as apotential treatment for idiopathic pulmonary fibrosis• Successful engineering of variable domains into the bispecific format- Advantages and Constraints of the bispecific format• Case study: The development of clinical candidate SAR156597• An overview of the safety, tolerability and PK of SAR156597• Development of a second generation bispecific format with improved propertiesDr Ercole Rao, Group Leader Antibody Engineering, Sanofi-Aventis, Germany11.30 Trifunctional bispecific antibodies in cancer therapy: Current development statusAfter the approval of anti-EpCAM x anti-CD3 catumaxomab for the treatment of malignant ascites, furtherclinical trials with known trifunctional antibodies were initiated. Thus, the clinical development programsfor ertumaxomab (anti-HER2/neu x anti-CD3) and lymphomun (anti-CD20 x anti-CD3) were continued.For this reason, together with the respective clinical results also pharmacodynamic data will be presentedthat demonstrate efficient tumor cell cytotoxicity mediated by the particular trifunctional antibody, e.g.lymphomun. Furthermore, secondary antigen-specific humoral and cell-mediated immune responses willbe shown that indicate vaccination-like effects induced by the appropriate trifunctional biopharmaceuticalDr Horst Lindhofer, CEO, Trion Pharma, Germany14.30 MeMo mice and common light chain antibodies for the discovery of human bispecificantibodiesPlease visit the webisite www.informa-ls.com/antibodies for more detailsDr John de Kruif, CSO, Merus, Switzerland15.00 Afternoon Tea plus Networking with Empowered Antibodies DelegatesPatent Protection for Therapeutic Antibodies and BioSuperiors –EU and US Comparison15.30 Creating meaningful patent protection for therapeutic antibodies – a comparisonbetween Europe and the United StatesIn a time when basic patents protecting the major therapeutic antibodies are about to expire, IPstrategies focus on follow-up protection for existing antibodies, and protection for new antibodies withdifferent or better properties. This presentation will give a comparative overview of the current grantingpolicy as practiced by the EPO and the USPTO, and discuss recent court cases. Further, significantdifferences with respect to the inventive step/non obviousness criterion between Europe and the UnitedStates will be highlighted.Tim Shea, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., USADr Ulrich Storz, Senior Partner, Michalski Hüttermann & Partner, GermanyHow are Alternative Scaffold Biologics Progressing Towards the Clinic?16.00 Engineering bispecific FynomAbs for therapeutic applicationsCovagen develops bispecific FynomAbs by fusing its fully human Fynomer binding proteins to antibodiesresulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment ofinflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allowsCovagen to create FynomAbs with tailored architectures and modes-of-action to maximize efficacy. Wewill show in case studies that FynomAbs represent an attractive new class of bispecific drug candidatesfor preclinical and clinical development.Dr Kristina Klupsch, Scientist, Covagen, Switzerland16.30 Enabling novel therapeutic concepts using multi-specific DARPinsThe DARPin platform allows the design of powerful drugs combining multiple functionalities. Thesemolecules enable novel therapeutic concepts with improved efficacy and PK as well as mechanism ofaction tailored to optimally address diseases with unmet medical needs. We will present examples fromour clinical and preclinical programs that have the potential to surpass current standards of care or breaknew therapeutic groundDr Daniel Steiner, Associate Director Lead Identification, Molecular Partners AG, Switzerland17.00 Identification and development of multispecific therapeutic proteins with lowdevelopability risk – case studies with AnticalinsThe development of multispecific therapeutic proteins opens the door to new and exciting biology.Pieris has developed a platform for the efficient generation of multispecific drug candidates (bi, tri- andbeyond) that seize the necessary pharmacological and pharmaceutical properties required to minimizeattrition and deliver on transformative product profiles. We will present data on one of our multispecificdrug candidate program – PRS190 – a multispecific therapeutic protein targeting the Th17 pathwayDr Laurent Audoly, Chief Scientific Officer, Head of R&D, Pieris AG, Switzerland17.30 Closing Remarks from the Chairman17.35 End of ConferenceSPONSORSHIP AND EXHIBITION OPPORTUNITIES FOR 2013Congress Sponsors:12.00 RECRUIT TandAb platform produces potent bispecific antibodiesThe TandAb technology comprises CD3 RECRUIT and CD16 RECRUIT effector modules for the respectiverecruitment of T and NK cells, and an anti-tumor antigen module to target and lyse cancer cells. SuchTandAb antibodies exhibit potent and efficacious tumor cell killing in vitro and in vivo. They possessexcellent safety profile, superior drug-like properties, and show activityin the clinicDr Eugene Zhukovsky, CSO, Affimed Therapeutics AG, Switzerland12.30 Spotlight presentationTechnology providers will host tutorials which are educational and address the benefit of their technologyin the field of Recombinant and Bispecific Antibodies. If you would like to host a tutorial please contact:Martin.cheung@informa.com, +44 (0)20 7017 493813.00 Lunch plus Networking with Empowered Antibodies CongressPOST-CONFERENCE WORKSHOP X: FRIDAY 14TH JUNE 2013ENGINEERING STRATEGIES TO REDUCE IMMUNOGENICIY FOR ANTIBODIES, FRAGMENTS AND CONJUGATESWhy attend?Discovery and Developability Assessment for Bispecific Antibodies14.00 Azymetric antibodies: The impact of engineering strategies on the developability ofbispecific therapiesAzymetric is an engineered bispecific antibody that retains the native IgG1 structure and biophysicalproperties. The developability of Azymetric antibodies will be discussed including the rationale behind thedesigns that favour fundamental biophysics, upstream and downstream manufacturability, and therapeuticpotential.Dr David Poon, Director, External R&D and Alliance, Zymeworks, CanadaThere is a wide range of immunogenicity observed whendeveloping therapeutics antibodies, indicating that there isscope to select or engineer a molecules to minimise potentialimmunogenicity. This workshop focuses on the various strategiesthat can be employed to reduce the likelihood of immunogenicityfor a molecule.Workshop Leader: David Bramhill, Founder, BramhillBiological Consulting, LLC, USARegistration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be providedSolubility and B-cell Presentation• Engineering proteins to improve solubility• Engineering proteins to improve stability• Engineering protein conjugates to improve solubilityImmunogenicity “101”• Antibody generation and affinity maturation• Dendritic cells• Presentation to B-cell receptors• MHC presentation to TCRWhy is Empowered Antibodies a must-attend event?1. Save time and moneyMeet all of your prospects and clients in one location over 2 days.The Empowered Antibodies Congress is made up from TWO co-located meetings:• Recombinant & Bispecific Antibodies • Antibody Drug Conjugates2. Increase your visibilityConference Exhibitor:• Showcase your latest scientific developments or launch new products and services• Position yourself as an industry-leading provider• Share your expertise and experiences with a senior-level audience -72% of delegates are Senior Level Management or above3. Meet only high level decision makers with a professional interest in the agendaBy being associated with such a meticulously researched and professionally structured meeting,you will maximise your investment, time and resources and most importantly your sellingMedia Partners:opportunities.The Empowered Antibodies Congress will provide you with flexible and tailored solutionswhich optimise your investment whilst meeting your specific business developmentrequirements. If any of the benefits above are important to your business, contact me:Martin Cheung;Tel: +44 (0) 20 7017 4938 Email: martin.cheung@informa.comJoin me on LinkedIn: www.linkedin.com/in/martincheungHistoric Engineering Attempts to Reduce Immunogenicity• Chimeric antibodies• Humanized antibodies• Improved humanization methodsT-cell Epitope Reduction• Predicting-threadding models for MHC• Measuring T-cell epitopesRegister online: www.informa-ls.com/antibodies • Phone: +44 (0) 20 7017 7481Email: registrations@informa-ls.com • Fax: +44 (0) 20 7017 7823 Please Quote: CQ3495New for2013

2 CONFERENCES - 2 AUDIENCES – 1 EXHIBITION11 - 13 JUNE2013HOTEL FIRA PALACEBARCELONASPAINCONFERENCE 1Recombinant &Bispecific AntibodiesCONFERENCE 2Antibody-Drug ConjugatesEmpowered Antibodies 2013 is Europe’s leading platform for discovering the latest in antibody engineering and therapeuticdevelopment. Our 2013 Congress is industry’s choice for discovering novel platforms and successful technologies to enhance thesafety, efficacy and potency of your drug. This event brings together key industry players, respected academics and leading serviceproviders to discuss strategies to ensure successful product development and market approval.Why is Empowered Antibodies 2013 a must-attend event?1. SAVE TIME AND MONEYMeet all of your prospects and clients in one location over 3 days.The Empowered Antibodies Congress is made up from TWO colocatedmeetings:• Recombinant & Bispecific Antibodies• Antibody-Drug Conjugates2. INCREASE YOUR VISIBILITY• Showcase your latest scientific developments or launch new products and services• Position yourself as an industry-leading provider• Share your expertise and experiences with a senior-level audience -72% of delegates are Senior-Level Management or above3. MEET ONLY HIGH LEVEL DECISIONMAKERS WITH A PROFESSIONALINTEREST IN THE AGENDABy being associated with such a meticulously researchedmeeting, you will maximise your investment, time andresources and most importantly your selling opportunities.Only senior-level delegates attend this event so you will onlymeet with decision makers who have a serious, genuine, andprofessional interest in the meeting.2012 Delegate Job Title ProfileDirector/CEO/VP - 22%Senior Management - 19%Scientist/Engineer/Academic - 53%Commercial - 6%2012 Geographical Delegate ProfileEastern Europe - 2%Northern Europe - 24%Rest of the World - 13%Southern Europe - 2%Western Europe - 59%SPONSORS AND EXHIBITORSPartnership opportunities and meeting new contactsBEFORE THE EVENTPre-arrange meetings with your target marketthrough the event’s Networking App.DURING THE EVENTEngage with your audience with over 10 hours of onsite networking time, 5 xinteractive workshop/seminars and 2 hours of discussion time.AFTER THE EVENTJoin the Empowered Antibodies dedicatedLinkedIn Group with over 250 membersThe Empowered Antibodies Congress will provide you with flexible and tailored solutions whichoptimise your investment whilst meeting your specific business development requirements. If any of thebenefits above are important to your business, contact me:Martin Cheung - Business Development Manager:Tel: +44 (0) 20 7017 4938 Email: martin.cheung@informa.comConnect with me on LinkedIn: www.linkedin.com/in/martincheung